Subgroups
Service Companies
Bayer Business Services
-
Thursday - April 25, 2013
First quarter of 2013:
Bayer: Life Sciences off to a good start in anniversary year
New pharmaceutical products spur growth at HealthCare, continuing strong development at CropScience, cost pressure at MaterialScience / Group sales up 2.1 percent to EUR 10,266 million / EBIT improves by 8.6 percent to EUR 1,771 million / EBITDA before special items increased by 0.4 percent to EUR 2,453 million / Net income rises 11.5 percent to EUR 1,160 million / Gratifying development in Emerging Markets / Group outlook for 2013 confirmed » more
-
Thursday - February 28, 2013
Financial News Conference
Full Year 2012 Results » more
-
Thursday - February 28, 2013
New products create optimism for the future
Bayer: continuing growth momentum
Group targets achieved in 2012 – sales and earnings before special items increase in all subgroups / Sales increase by 8.8 percent to EUR 39,760 million / EBIT EUR 3,960 million (minus 4.6 percent) – Net income EUR 2,446 million (minus 1.0 percent) / Further accounting measures for legal claims / EBITDA before special items rises by 8.8 percent to EUR 8,284 million / Core earnings per share improve by 10.8 percent to EUR 5.35 / Encouraging growth in the emerging markets / Steady progress with innovation pipeline strengthens life-science businesses / Forecast for anniversary year 2013: continuing record development » more
-
Monday - December 10, 2012
Distinction for outstanding HR marketing activities:
Bayer JobApp wins HR Excellence Award » more
-
Thursday - December 6, 2012
Innovative and flexible solutions for reducing vehicle fleet CO2:
Bayer awarded International Fleet Green Award once again
Objective achieved ahead of deadline: 20 percent reduction in CO2 emissions of vehicle fleet since 2008 » more
-
Wednesday - November 14, 2012
Press Forum
Bayer's Perspective on Innovation 2012 » more
-
Wednesday - November 14, 2012
Perspective on Innovation 2012:
Bayer: improving people’s lives through innovation
Some EUR 3 billion for research and development in 2012 / More than 600 patent applications submitted last year / Currently 35 clinical development projects in the pharmaceuticals pipeline / Five pharmaceutical products with approximate peak annual sales potential of more than EUR 5.5 billion / Strong CropScience pipeline with peak sales potential exceeding EUR 4 billion / Increasing significance of partnerships – more than 800 R&D collaborations » more
-
Tuesday - October 30, 2012
Bayer AG Third Quarter 2012 Results and News Conference Call » more
-
Tuesday - October 30, 2012
Third quarter of 2012:
Bayer on track for a successful 2012
Upward trend at HealthCare and CropScience continues / Sales advanced by 11.5 percent to EUR 9,665 million / EBIT of EUR 838 million (minus 23.7 percent) / EBITDA before special items improved by 2.2 percent to EUR 1,845 million / Net income of EUR 528 million (minus 17.8 percent) / Further progress with innovation pipeline / Group forecast for 2012 confirmed » more
-
Tuesday - July 31, 2012
Strong business performance in the second quarter of 2012:
Bayer raises guidance for the full year
Sales increased by 10.0 percent to a record EUR 10,177 million / CropScience and HealthCare sustained strong momentum, MaterialScience improved further / EBIT of EUR 750 million (minus 41.1 percent) impacted by special items – risk provisions established for litigations / EBITDA before special items rose by 6.7 percent to EUR 2,172 million / Net income of EUR 494 million (minus 33.9 percent) » more
-
Friday - June 1, 2012
Change on the Executive Board
Wilhelm Oehlschläger is new Labor Director
Norbert Fieseler retires » more
Copyright @ Bayer AG